MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Cameron Health’s FDA date is good news for Boston Scientific

Cameron Health’s FDA date is good news for Boston Scientific

By

leadless ICD

Cameron Health landed an April date with the FDA’s circulatory devices panel to review a pre-market approval application for its lead-free subcutaneous implantable cardioverter defibrillator, or S-ICD.

The S-ICD system, unlike traditional ICDs, sits just beneath the skin and does not rely on wires relayed through blood vessels and connected to the heart in order to provide heart rhythm therapy.

The device, which has been the only lead-free cardiac rhythm implant on the market since winning CE Mark approval in the European Union in 2009, will get the FDA treatment on April 26, according to the watchdog agency.

That’s good news for Boston Scientific (NYSE:BSX), which earlier this month said it would pay up to $1.35 billion for Cameron Health.

Cameron filed its PMA in December 2011, making the quick FDA turnaround a positive sign for its steward-to-be. Nevertheless the news didn’t win much love from Wall Street today, where BSX shares were down 7¢ to $6.05 as of about 3 p.m.

"To us, FDA scheduling a panel to review the lead-less ICD so urgently … could suggest basically 2 things," analysts at Leerink Swann wrote in a note to investors. "(1) FDA must believe this is important new technology – particularly in the context of ongoing transvenous lead performance concerns (which the S-ICD aims to avoid), (2) FDA must have a basically positive bias toward the technology."

Either way, that’s a windfall for med-tech titan Boston Scientific and a possible setback for Edwards Lifesciences (NYSE:EW), which is not now likely to win its own panel date in April to review the "high-risk" patient group, cohort A, in its Sapien transcatheter heart valve PMA bid.

"Based on the FDA’s tentative panel meeting calendar, the next possible date for an EW Sapien panel now appears May 24," according to the analysts. "Clearly, the longer cohort A approval drags out, the more risk to numbers and the greater the likelihood of further downward estimate revisions."

EW shares were down 1% to $70.75 in late afternoon trading.

The April panel will also consider HeartWare’s implantable rotary blood pump, according to the FDA notice.

In case you missed it

RSS From Medical Design & Outsourcing

  • Study finds single-use bronchoscopes reduce hospital readmission rates by half
    A study of 14,228 bronchoscopy procedures found sterile, disposable scopes reduced readmission rates by more than half. The study, authored by Ambu consultant Dr. Hudson Garrett, analyzed procedures at inpatient hospitals as well as outpatient ambulatory facilities. He found that 3.6 percent of patients treated with a single-use, flexible bronchoscope were readmitted within 30 days,… […]
  • Medtronic hires social-media-minded chief medical officer for its gastrointestinal unit
    Medtronic (NYSE:MDT) today said it has hired Dr. Austin Chiang as the first chief medical officer of the medical device maker’s gastrointestinal business. Chiang is an assistant professor of medicine at Sidney Kimmel Medical College and director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, both in Philadelphia. He holds a master’s degree… […]
  • Boston Scientific settles patent dispute with Micro-Tech Endoscopy over hemostasis clips
    Boston Scientific (NYSE:BSX) said yesterday that it has resolved its patent infringement litigation against Micro-Tech Endoscopy over hemostasis clips used in endoscopy procedures. Boston Scientific said it will grant a five-year, royalty-bearing license to Ann-Arbor, Mich.-based Micro-Tech for the patented hemostasis clip technology. The clips are applied to tissue or blood vessels to stop gastrointestinal… […]
  • How vapor degreasing is helping to future-proof medical device reliability
    Precision cleaning of electronic medical devices boosts reliability. Jay Tourigny, MicroCare COVID-19 has brought the importance of wearable and remote monitoring and diagnostic devices to the forefront. But these devices, with their intricate PCBAs (printed circuit board assemblies) must deliver reliable and consistent performance, particularly as they are often used in devices that are life-sustaining.… […]
  • Freudenberg Medical launches SpeakFree HME valve for laryngectomy care
    Freudenberg Medical today announced the commercial launch of its Blom-Singer SpeakFree heat and moisture exchange (HME) hands free valve. The device is designed for people who have undergone a total laryngectomy, or the removal of a person’s larynx or voice box, resulting in loss of speech. Carpinteria, California-based Freudenberg Medical’s InHealth Technologies unit said its… […]
  • Luminopia’s new FDA-approved therapy uses TV to treat lazy eye in kids
    Luminopia announced today that it received FDA de novo approval for its prescription therapy for improving vision in children with lazy eye. Cambridge, Massachusetts-based Luminopia’s prescription Luminopia One holds indication for improvement in visual acuity in children between ages four and seven with lazy eye (amblyopia) associated with anisometropia and/or mild strabismus, having received treatment… […]
  • Tessy Plastics has a deal for a new campus in New York
    Tessy Plastics today said it has a deal to buy a three-building campus totaling about 1.5 million square feet in Webster, New York. The three buildings — 200, 210 and 214 at 800 Phillips Road, formerly owned by Xerox — are about an hour’s drive from Skaneateles, New York-based Tessy’s other facilities in Upstate New York. The… […]
  • Diversity in medtech: Just 21% of executive roles are held by women
    The prevalence of women in corporate leadership positions within the medical device industry remains low, and the rate of increase is stagnant despite new initiatives to increase diversity in the industry. Just 21% of top executives at the world’s 100 world’s biggest medical device companies are women, according to an analysis of Medical Design &… […]
  • Intuitive Surgical highlights supply chain risk, addresses Medtronic’s Hugo launch
    Intuitive Surgical executives today said delays and price increases are working their way through the medtech supply chain, likely resulting in higher production costs in the months ahead and the potential for delayed development and regulatory activity. “I don’t think I can say it’s getting better. It’s a difficult situation and will continue for some… […]
  • Intuitive Surgical names new C-suite leaders, reports Street-beating Q3
    Intuitive Surgical (NSDQ:ISRG) today announced changes in the ranks of its senior leadership as the surgical robotics maker released Q3 results that exceeded expectations. Sunnyvale, California-based Intuitive launched two new functional organizations — Strategy and Growth, and Global Business Services — and named leaders who will take over effective Jan. 1. Dave Rosa, a 25-year… […]
  • Johnson & Johnson discloses two-year delay for Ottava robot
    Johnson & Johnson (NYSE:JNJ) today confirmed that it experienced a “temporary setback” with its Ottava surgical robotic system. Speaking on the company’s third-quarter earnings call, transcribed by SeekingAlpha, J&J EVP Joseph Wolk said that while the company maintains its commitment to developing a general surgery offering with Ottava, the platform’s development timeline has been pushed back about two years… […]

Leave a Reply